2770858-49-4
2770858-49-4
Chemical Structure
Biological Activity: Lunsekimig (SAR443765) is a nanobody composed of 5 VH domains that targets both TSLP and IL-13. Lunsekimig blocks the functional effects of TSLP and IL-13, inhibits related inflammatory signals, and improves lung function associated with type 2 inflammation. Lunsekimig can be used in research on asthma and type 2 inflammation[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lunsekimig | 99.00% | Lunsekimig (SAR443765) is a nanobody composed of 5 VH domains that targets both TSLP and IL-13. Lunsekimig blocks the functional effects of TSLP and IL-13, inhibits related inflammatory signals, and improves lung function associated with type 2 inflammation. Lunsekimig can be used in research on asthma and type 2 inflammation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Deiteren A, et al. A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers. Clinical and translational science. 2024 Jun;17(6):e13864. [Content Brief]
- [2]. Deiteren A, et al. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. The European respiratory journal. 2025 Apr;65(4):2401461. [Content Brief]
Keywords
